Galapagos announces new collaboration with AstraZeneca

04-Aug-2006

Galapagos NV announced that its service division BioFocus DPI has entered a new drug discovery collaboration with AstraZeneca. This collaboration marks the first time AstraZeneca has selected BioFocus DPI to provide drug discovery services. Under the terms of the agreement, BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca's respiratory and inflammatory drug discovery programs. Total contract value for Galapagos is EUR650,000.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance